Y Intercept Hong Kong Ltd Reduces Position in DaVita Inc. (NYSE:DVA)

Y Intercept Hong Kong Ltd decreased its holdings in DaVita Inc. (NYSE:DVA) by 11.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,595 shares of the company’s stock after selling 879 shares during the period. Y Intercept Hong Kong Ltd’s holdings in DaVita were worth $986,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. FMR LLC boosted its holdings in DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after buying an additional 154,061 shares during the period. Glenmede Trust Co. NA lifted its position in shares of DaVita by 731.6% during the third quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock worth $20,207,000 after acquiring an additional 108,446 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after acquiring an additional 92,014 shares during the period. KBC Group NV grew its position in shares of DaVita by 27.3% in the third quarter. KBC Group NV now owns 313,519 shares of the company’s stock valued at $51,395,000 after purchasing an additional 67,250 shares in the last quarter. Finally, International Assets Investment Management LLC purchased a new position in shares of DaVita in the third quarter valued at $10,346,000. Institutional investors own 90.12% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on DVA. Barclays upped their price target on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 18th. Cowen reaffirmed a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company. According to MarketBeat.com, DaVita currently has an average rating of “Hold” and an average target price of $162.80.

DaVita Price Performance

DVA opened at $146.60 on Friday. The stock’s 50 day moving average price is $160.74 and its 200-day moving average price is $158.05. DaVita Inc. has a 52-week low of $124.70 and a 52-week high of $179.60. The stock has a market capitalization of $11.73 billion, a PE ratio of 13.65, a price-to-earnings-growth ratio of 1.07 and a beta of 0.93. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, equities research analysts predict that DaVita Inc. will post 10.76 EPS for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.